- Home
- ROOT vs GYRE Comparison
ROOT vs GYRE Comparison
Compare ROOT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- GYRE
- Stock Information
- Founded
- ROOT 2015
- GYRE 2002
- Country
- ROOT United States
- GYRE United States
- Employees
- ROOT N/A
- GYRE N/A
- Industry
- ROOT Property-Casualty Insurers
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- GYRE Health Care
- Exchange
- ROOT Nasdaq
- GYRE Nasdaq
- Market Cap
- ROOT 2.3B
- GYRE 897.1M
- IPO Year
- ROOT 2020
- GYRE N/A
- Fundamental
- Price
- ROOT $126.00
- GYRE $7.42
- Analyst Decision
- ROOT Buy
- GYRE
- Analyst Count
- ROOT 6
- GYRE 0
- Target Price
- ROOT $134.80
- GYRE N/A
- AVG Volume (30 Days)
- ROOT 457.1K
- GYRE 253.7K
- Earning Date
- ROOT 08-06-2025
- GYRE 08-12-2025
- Dividend Yield
- ROOT N/A
- GYRE N/A
- EPS Growth
- ROOT N/A
- GYRE N/A
- EPS
- ROOT 3.16
- GYRE 0.02
- Revenue
- ROOT $1,271,000,000.00
- GYRE $100,643,000.00
- Revenue This Year
- ROOT $22.06
- GYRE $21.04
- Revenue Next Year
- ROOT $10.86
- GYRE $89.64
- P/E Ratio
- ROOT $40.51
- GYRE $93.77
- Revenue Growth
- ROOT 98.66
- GYRE N/A
- 52 Week Low
- ROOT $34.04
- GYRE $6.11
- 52 Week High
- ROOT $181.14
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ROOT 42.66
- GYRE 39.71
- Support Level
- ROOT $121.41
- GYRE $7.26
- Resistance Level
- ROOT $138.31
- GYRE $8.00
- Average True Range (ATR)
- ROOT 8.32
- GYRE 0.49
- MACD
- ROOT -2.20
- GYRE -0.07
- Stochastic Oscillator
- ROOT 16.45
- GYRE 10.36
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.